Kenvue Inc. (KVUE) is a Consumer Discretionary stock trading at $18.98 (as of 2026-07-17), with a market capitalization of $36.44B and a trailing P/E of 22.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
Kenvue sells consumer health products across self care, skin health and beauty, and essential health under brands like Tylenol, Nicorette, Zyrtec, Neutrogena, Aveeno, OGX, and Listerin, and it makes money from net sales of these products.
Kenvue's profit engine is the same across its portfolio, net sales from brand-led consumer health categories, with profitability then flowing through to the company operating margin.
| Self Care | $1.7B |
| Skin Health & Beauty | $1.0B |
| Essential Health | $1.2B |
Business quality (Mixed): Segment disclosures are clear by category (Self Care, Skin Health and Beauty, Essential Health), but no operating KPIs were provided here, so investors have fewer visibility points beyond financial margins.
Valuation: At 22× earnings, KVUE trades 18% below the Consumer Goods average (26×). Note: one-time items can distort reported P/E.
| Price | $18.98 |
| Market Cap | $36.44B |
| P/E Ratio | 22.5 |
| EV / EBITDA | 11.6 |
| Price / Book | 3.44 |
| Price / Sales | 2.38 |
| FCF Yield | 5.0% |
| DCF Value (model) | $13.53 |
| DCF Upside vs Price | -28.7% |
| Revenue (TTM) | $15.12B |
| Net Margin | 9.7% |
| Revenue Growth (YoY) | 4.5% |
| EPS Growth (YoY) | 47.1% |
| FCF Growth (YoY) | 40.6% |
| Altman Z-Score | 2.17 (grey) |
| Piotroski F-Score | 6/9 (moderate) |
| Stock P/E | 22.5 |
| Sector P/E (Consumer Discretionary) | 21.6 |
| Industry P/E (Consumer Goods) | 27.6 |
| vs Sector | 4.2% |
| vs Industry | -18.7% |
| Top Institutional Holder | VANGUARD GROUP INC ($4.05B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Consumer Discretionary |
| Industry | Consumer Goods |
| CEO | Kirk L. Perry |
| Employees | 22,000 |
| Country | US |
| IPO Date | 2023-05-04 |
Data as of 2026-07-17.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.